A DNA-based blood test is changing the future of cancer detection by spotting more than 50 types of the disease before symptoms appear.
Known as Galleri, the test scans the bloodstream for tiny fragments of tumour DNA shed by cancer cells, allowing doctors to identify early signs of cancer, pinpointing where it is developing, long before it becomes life-threatening, a report by The Independent revealed.
Developed by US-based biotech company Grail, the test is being evaluated by the UK’s National Health Service (NHS) and could mark a turning point in global cancer screening.